RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 133 filers reported holding RECURSION PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.76 and the average weighting 2.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $257,000 | +7.1% | 24,112 | -18.2% | 0.10% | +16.7% |
| Q2 2022 | $240,000 | +17.1% | 29,472 | +2.8% | 0.08% | +31.2% |
| Q1 2022 | $205,000 | -53.6% | 28,672 | +11.2% | 0.06% | -44.8% |
| Q4 2021 | $442,000 | +16.3% | 25,782 | +56.0% | 0.12% | +12.6% |
| Q3 2021 | $380,000 | -22.4% | 16,532 | +23.1% | 0.10% | -25.9% |
| Q2 2021 | $490,000 | – | 13,432 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Obvious Management Services, L.L.C. | 3,985,087 | $42,401,000 | 100.00% |
| Two Sigma Ventures, LP | 903,400 | $9,612,000 | 100.00% |
| DCVC Opportunity Fund II GP, LLC | 3,951,141 | $42,040,000 | 54.37% |
| Data Collective IV GP, LLC | 5,941,120 | $63,214,000 | 49.97% |
| MIC Capital Management UK LLP | 8,451,758 | $89,927,000 | 16.21% |
| MV Management XI, L.L.C. | 1,971,908 | $20,981,000 | 15.20% |
| ArchPoint Investors | 1,116,126 | $11,876,000 | 4.85% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $16,058,000 | 2.00% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,251,971 | $23,961,000 | 1.00% |
| Duquesne Family Office | 1,385,950 | $14,747,000 | 0.84% |